147 Organizations Rally to Defend Addiction Treatment Funding as Budget Battles Loom

The Addiction Policy Forum and 146 national, state, and local organizations sent Congress a letter last week urging lawmakers to maintain funding for substance use disorder programs in the fiscal year 2027 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. The timing carries weight: the Trump Administration recently proposed cutting HHS funding by approximately 12.5 percent—roughly $15.8 billion—creating uncertainty for addiction treatment providers, researchers, and advocates who have watched federal support expand over the past decade only to face potential reversal.

The coalition letter lands during a particularly fraught budget season. In January 2026, the administration abruptly terminated hundreds of SAMHSA grants, disrupting mental health and addiction services across dozens of states. Now the White House FY2027 budget proposal targets further cuts to programs housed within the Centers for Disease Control and Prevention, the Health Resources and Services Administration, and the Substance Abuse and Mental Health Services Administration—agencies the administration plans to consolidate under a newly proposed body called the Administration for a Healthy America. Whether that reorganization would preserve existing program capacity or function primarily as a vehicle for budget reductions remains unclear.

The letter specifies programs the coalition considers essential across what advocates describe as the "continuum of care" for substance use disorders. Research funding forms the foundation. The National Institutes of Health, the National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute of Mental Health generate the scientific evidence that determines which treatments, services, and prevention strategies actually work. Without ongoing research appropriations, the field loses the capacity to distinguish effective interventions from those that sound promising but deliver minimal measurable benefit—a distinction that matters enormously when resources remain scarce and overdose deaths continue at levels unimaginable two decades ago.

SAMHSA programs represent the operational infrastructure translating research findings into accessible services. The agency coordinates national efforts addressing behavioral health conditions through prevention initiatives, treatment expansion, and recovery support. The coalition letter highlights several SAMHSA prevention programs facing uncertain futures. The Center for Substance Abuse Prevention coordinates efforts across states focusing on preventing substance use initiation, stopping progression from casual to problematic use, and reducing harms associated with existing substance use patterns. The Sober Truth on Preventing Underage Drinking Act program strengthens community partnerships specifically targeting alcohol use among youth aged 12 through 20. Screening, Brief Intervention, and Referral to Treatment emphasizes early identification through systematic screening—particularly for underage drinking and opioid use—followed by timely intervention and treatment referrals when appropriate.

Crisis response funding proves critical during a period when overdose reversals and suicide prevention calls have strained first responder systems nationwide. SAMHSA programs authorized through the Comprehensive Addiction and Recovery Act, the First Responder Training initiative focusing on overdose reversal, and the Improving Access to Overdose Treatment program expand training and naloxone access for emergency personnel. The 988 Suicide and Crisis Lifeline connects individuals experiencing acute crises to trained mental health professionals capable of providing immediate intervention. Defunding these programs would leave communities scrambling to replace infrastructure built incrementally over years.

Treatment infrastructure depends heavily on SAMHSA grant programs that established much of the nation's frontline capacity for medication-assisted treatment and comprehensive care. Opioid Treatment Programs—certified facilities providing FDA-approved medications like methadone and buprenorphine alongside counseling and behavioral therapies—operate largely through funding combinations including SAMHSA support. State Opioid Response grants have funded prevention efforts, overdose reversal medication distribution, treatment services, and recovery supports across jurisdictions with vastly different resources and political environments. The Substance Use Prevention, Treatment, and Recovery Services Block Grant program assists states in planning, implementing, and evaluating interventions preventing and treating substance use disorders. The Community Mental Health Services Block Grant provides states with funding for comprehensive mental health services.

Criminal justice programs address the reality that many individuals with substance use disorders cycle through jails and prisons rather than treatment facilities. SAMHSA's Criminal Justice Activities programs aim to reduce recidivism and promote rehabilitation. Drug Courts provide judicial supervision combined with treatment services addressing both substance use and co-occurring mental health conditions. Research consistently demonstrates Drug Courts reduce criminal justice involvement and improve health outcomes compared to incarceration without treatment access. Yet these programs require sustained funding to maintain specialized staff, treatment contracts, and coordination mechanisms connecting courts to community providers.

The coalition letter arrives as Congress confronts competing pressures. Budget reconciliation debates continue around the One Big Beautiful Bill Act, legislation that could fundamentally reshape Medicaid funding and eligibility—changes affecting how millions of people access addiction treatment. Fiscal conservatives argue federal spending requires substantial cuts, pointing to national debt levels and questioning whether existing addiction programs deliver outcomes justifying their budgets. Last month's House Subcommittee on Health Care and Financial Services roundtable examined that question directly, with Chairman Glenn Grothman noting mental health spending has increased 241 percent between 2000 and 2021 while outcomes appear to have worsened rather than improved.

That disconnect between spending and outcomes complicates advocacy efforts. Simply defending existing funding levels proves insufficient when lawmakers and constituents question whether current approaches work. The coalition letter addresses this tension by emphasizing that funding supports "research efforts that generate the scientific evidence needed to ensure treatments, services, and resources effectively prevent and treat SUDs." The argument holds that cutting funding eliminates the very research and evaluation mechanisms required to distinguish effective programs from ineffective ones—making it impossible to improve outcomes through evidence-based allocation.

The political environment differs substantially from the period when many of these programs expanded. Bipartisan support for addressing the opioid epidemic drove funding increases throughout the 2010s and early 2020s. That consensus has fractured amid debates over harm reduction approaches, medication-assisted treatment philosophies, and broader questions about federal versus state responsibility for public health crises. Robert F. Kennedy Jr.'s role as HHS Secretary and emphasis on what he describes as addressing "spiritual malaise" through faith-based programming has shifted departmental priorities in ways that worry advocates emphasizing evidence-based medical interventions.

The proposed 12.5 percent HHS budget reduction would affect addiction and mental health services disproportionately relative to other health programs. Unlike Medicare, which commands enormous political constituencies and faces statutory obligations, discretionary programs like SAMHSA grants lack similar protections. When overall agency budgets shrink, programs serving marginalized populations experiencing addiction and mental illness typically absorb outsized cuts. The coalition letter functions partly as an attempt to create political visibility for programs that lack the organized lobbying power of hospital associations, pharmaceutical manufacturers, or physician groups.

Whether Congress heeds the coalition's call depends on factors beyond the letter itself. Appropriations battles in divided government often produce continuing resolutions maintaining existing funding rather than the increases advocates request or the cuts administrations propose. The FY2027 Labor-HHS appropriations bill likely won't receive final passage until well into the fiscal year, if recent patterns hold. That creates prolonged uncertainty for treatment providers operating on grant cycles who must decide whether to hire staff, sign facility leases, and commit to program expansions without knowing whether funding will materialize.

The 147 organizations signing the letter represent diverse constituencies—patient advocacy groups, professional associations, treatment providers, research institutions, and state agencies. That breadth matters politically. When addiction treatment advocates coordinate across organizational lines and speak with relative unity, lawmakers face pressure from multiple directions rather than dismissing concerns as representing narrow special interests. Whether that pressure proves sufficient to maintain funding when the administration explicitly seeks cuts and when broader fiscal debates dominate congressional attention remains uncertain.

For addiction treatment providers navigating budget uncertainty, the coalition letter offers some reassurance that national organizations are actively defending funding even as it highlights the precarious position of programs many communities now depend on. Facilities that opened in recent years with State Opioid Response grants, prevention programs launched with SAMHSA support, and Drug Courts established through federal seed funding all face questions about sustainability if appropriations shrink substantially. Some programs might transition to state funding or alternative revenue sources. Others, particularly those serving populations unable to pay for treatment, would likely close.

The letter emphasizes that federal investments have been "critical in reducing overdose fatalities while also strengthening communities, supporting families, and improving health outcomes nationwide." That assertion faces empirical challenges. Overdose deaths have declined modestly from 2023 peaks, but remain dramatically higher than levels seen before fentanyl's spread through drug supplies. Whether existing programs deserve credit for preventing even worse outcomes or bear responsibility for failing to contain the crisis more effectively depends partly on counterfactual assumptions impossible to test. Advocates argue funding should increase to match the scale of need. Critics contend results don't justify current spending levels, much less increases.

Congressional appropriators will ultimately decide which position prevails when they draft the FY2027 Labor-HHS bill. The coalition letter ensures that addiction treatment funding receives at least some attention in debates likely dominated by high-profile programs like the National Institutes of Health, the CDC, and Medicare. Whether attention translates to maintained or increased funding, or simply slows the pace of cuts, depends on negotiations still months away from resolution. Treatment providers, researchers, and people seeking help for substance use disorders will live with the consequences.